Related Article from Barriers to Integrating Gene Profiling for Stage II Colon Cancer

Related Article from Barriers to Integrating Gene Profiling for Stage II Colon Cance

Related Article from The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men

Related Article from The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Me

Supplementary Table S1 from Src Continues Aging: Current and Future Clinical Directions

Supplementary Table S1 from Src Continues Aging: Current and Future Clinical Direction

sj-pdf-1-ctj-10.1177_17407745231176445 – Supplemental material for BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

Supplemental material, sj-pdf-1-ctj-10.1177_17407745231176445 for BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials by Liyun Jiang, Peter F Thall, Fangrong Yan, Scott Kopetz and Ying Yuan in Clinical Trials</p

Supplementary Figure 3 from Mutation Status of <i>RAS, TP53</i>, and <i>SMAD4</i> is Superior to Mutation Status of <i>RAS</i> Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases

Supplementary Figure 3. Overall survival (OS) and recurrence-free survival (RFS) by RAS mutation status.</p

Supplementary Data from Mutation Status of <i>RAS, TP53</i>, and <i>SMAD4</i> is Superior to Mutation Status of <i>RAS</i> Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases

Supplementary Table 1. Genes and codon tested for adequate amplicons Supplementary Table 2. Multivariable hazard ratios (HRs) for OS and RFS by RAS mutation status in 507 patients Supplementary Table 3. Demographic and clinicopathologic characteristics of 313 patients with unresectable colorectal metastases.</p

Supplementary Figure 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Figure 3: The MRC significantly predicted recurrence-free interval regardless of the adjuvant chemotherapy treatment. The Kaplan Meier plots from: A, B, C and D) untreated patients; E, F, G and H) patients treated with 5-FU; A, B, E and F) from the fresh-frozen specimens in cohort-1; and C, D, G and H) from the FFPE specimens in cohorts 2 and 3.</p

Supplementary Table 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Table 3: Spearman's rho correlation coefficients of MRC vs clinicopathological risk factors for all the clinical cohorts.</p

Supplementary Figure 2 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Figure 2: CONSORT diagram for patients and specimens from both fresh-frozen and FFPE clinical validation cohorts. A) Fresh-frozen cohort (cohort-1), B) FFPE cohort (cohorts 2 and 3).</p

Combined targeting of SRC and MEK inhibits compensatory survival signaling pathways in multiple KRAS-mutated CRC cell lines treated with MEK inhibitors alone.

Western blots performed to detect changes in the levels of the signaling factors pSRC, pFAK, and pERK in multiple KRAS-mutated CRC cell lines are shown. Changes in phosphorylation levels were compared with their respective total levels. Vinculin was used as a loading control. C, control; T, trametinib; D, dasatinib; T+D, trametinib and dasatinib. The numbers below the blots denote the phospho-protein levels relative to total protein levels in each sample (Control cells standardized to 1).</p